KRAS and colorectal carcinoma: Several immune-related pathways were significantly down-regulated in KRAS-mutant compared to that of KRAS wild-type CRC patients, namely, Th1 and Th2 cell differentiation, T cell receptor signaling, and nuclear factor kappa-B (NF-κB) signaling pathways (Fig. 1c).